CompletedPhase 1NCT01839240
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Principal Investigator
- Olatoyosi OdenikeUniversity of Chicago Comprehensive Cancer Center
- Intervention
- azacitidine(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2019
Study locations (1)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01839240 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.